Amgen Inc. (NASDAQ:AMGN) Stock Holdings Lessened by Scarborough Advisors LLC

Scarborough Advisors LLC lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 2.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,794 shares of the medical research company’s stock after selling 40 shares during the quarter. Scarborough Advisors LLC’s holdings in Amgen were worth $468,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of the business. Capital Performance Advisors LLP bought a new position in shares of Amgen during the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen during the 3rd quarter valued at approximately $29,000. Heck Capital Advisors LLC bought a new position in Amgen during the 4th quarter worth $36,000. PrairieView Partners LLC increased its position in Amgen by 118.3% in the fourth quarter. PrairieView Partners LLC now owns 179 shares of the medical research company’s stock worth $46,000 after buying an additional 97 shares during the period. Finally, Wingate Wealth Advisors Inc. bought a new stake in Amgen in the fourth quarter valued at $52,000. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In related news, EVP Murdo Gordon sold 8,771 shares of the firm’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the sale, the executive vice president now directly owns 44,186 shares in the company, valued at approximately $13,025,590.94. This trade represents a 16.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 35,405 shares of company stock valued at $10,410,596. Company insiders own 0.69% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Jefferies Financial Group restated a “buy” rating and set a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Leerink Partners cut their price target on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Wells Fargo & Company reduced their price objective on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research report on Friday, January 10th. Piper Sandler Companies restated an “overweight” rating and issued a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Finally, StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $314.09.

Amgen Stock Performance

AMGN opened at $291.16 on Friday. The business has a fifty day simple moving average of $273.75 and a 200-day simple moving average of $302.14. The firm has a market cap of $156.51 billion, a PE ratio of 38.56, a P/E/G ratio of 3.01 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities analysts predict that Amgen Inc. will post 20.59 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.27%. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.